A Comparison of the Dexamethasone Implant (Ozurdex®) and Inferior Fornix-Based Sub-Tenon Triamcinolone Acetonide for Treatment of Inflammatory Ocular Diseases
| Autor: | Raphaelle Ores, Neila Sedira, Marie-Hélène Errera, Mark Westcott, Emmanuel Héron, Amine Bensemlali, José-Alain Sahel, Ana Catarina Pratas, Bahram Bodaghi, Pablo Goldschmidt, Sabrina Falah, Jonathan Benesty, Jérôme Smadja |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Triamcinolone acetonide Time Factors Triamcinolone Injection Tenon Capsule Mortise and tenon Visual Acuity Triamcinolone Acetonide Dexamethasone Uveitis 03 medical and health sciences 0302 clinical medicine Ophthalmology medicine Immunology and Allergy Humans Glucocorticoids Aged Retrospective Studies 030203 arthritis & rheumatology Drug Implants business.industry Fornix Middle Aged medicine.disease eye diseases Treatment Outcome 030221 ophthalmology & optometry Female sense organs Implant Injections Intraocular business Tomography Optical Coherence medicine.drug Follow-Up Studies |
| Zdroj: | Ocular immunology and inflammation. 27(2) |
| ISSN: | 1744-5078 |
| Popis: | To evaluate the efficacy and safety of dexamethasone (DEX) implant compared with inferior fornix-based sub-Tenon triamcinolone injection (PSTA) for treatment of uveitis.A total of 48 eyes received DEX and 49 eyes received PSTA as the first treatment.A total of 31 eyes were implanted with DEX relapsed (64.5%) after the first injection, while 32 eyes were injected with PSTA as the first treatment relapsed (65.3%). Kaplan-Meier estimated survival to overall relapse after the first injection was a mean 20 months± 3.6 months for DEX (median,7) and 14 months± 1.9 months (median,9) for the PSTA (P = 0.505). Of 49 eyes receiving the PSTA implant as the first treatment, inflammation persisted in 14.3% after the first injection but persisted in none after the DEX injection (P = 0.005).DEX implantation achieved a higher rate of disease control in the initial 12 weeks postinjection with a relative equivalence in the duration of effect and relapse rates when compared with PSTA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|